Publication & Citation Trends
Publications
0 total
Characterization of Patients With Unresectable Hepatocellular Carcinoma in REFLECT Who Achieved Tumor Response or Alpha-Fetoprotein Response When Treated With Lenvatinib
Cited by 0
Semantic Scholar
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma
Cited by 2
Semantic Scholar
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
Cited by 130
Semantic Scholar
LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma.
Cited by 4
Semantic Scholar
Association between treatment‐emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study OA
Cited by 6
Semantic Scholar
Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.
Cited by 9
Semantic Scholar
LBA3 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
Cited by 31
Semantic Scholar
Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT OA
Cited by 7
Semantic Scholar
Research Topics
Hepatocellular Carcinoma Treatment and Prognosis
(23)
Cancer Immunotherapy and Biomarkers
(10)
Renal cell carcinoma treatment
(10)
Pancreatic and Hepatic Oncology Research
(7)
Cancer Mechanisms and Therapy
(7)
Affiliations
Northwell Health
NewYork–Presbyterian Hospital
Cornell University
Lenox Hill Hospital
New York Hospital Queens